Table 1.
Characteristics of patients admitted to the ICU for severe COVID-19 according to viral reactivation.
| Characteristics | No viral reactivation | Viral reactivation | P |
|---|---|---|---|
| n | 37 | 63 | |
| Age (years) | 58 [49–67] | 60 [53–67] | 0.39 |
| Male | 26 (70) | 47 (75) | 0.81 |
| Immunosuppression | 13 (36) | 25 (42) | 0.75 |
| Solid tumor | 4 (11) | 5 (8) | |
| Hematological malignancy | 10 (27) | 5 (8) | |
| Solid organ transplantation | 0 (0) | 10 (16) | |
| HIV infection | 0 (0) | 1 (2) | |
| Autoimmune or inflammatory disease | 4 (11) | 8 (13) | |
| Valaciclovir prophylaxis | 7 (19) | 3 (5) | 0.05 |
| Hematopoietic cell transplantation | 5 (14) | 1 (2) | 0.05 |
| Antibiotics prior to ICU admission | 14 (38) | 31 (49) | 0.37 |
| SAPSII at admission | 25 [19–39] | 29 [18–38] | 0.83 |
| ICU admission | |||
| Leukocytes (G/L) | 5.89 [4.43–8.40] | 7.37 [5.76–9.73] | 0.02 |
| Lymphocyte (G/L) | 0.82 [0.58–1.16] | 0.77 [0.50–1.05] | 0.42 |
| IL-6 (ng/mL) | 82 [54–157] | 85 [42–126] | 0.85 |
| Lactate | 1.1 [0.8–1.6] | 1.20 [1.0–1.4] | 0.60 |
| Ferritin | 1094 [499–1670] | 1311 [654–2305] | 0.16 |
| Therapeutics | |||
| dexamethasone | 6 (16) | 27 (44) | 0.01 |
| lopinavir/ritonavir | 5 (14) | 8 (13) | 1.00 |
| eculizumab | 2 (5) | 8 (13) | 0.41 |
| tocilizumab | 3 (8) | 2 (3) | 0.54 |
| Mechanical ventilation | 17 (46) | 37 (59) | 0.30 |
| Vasopressors | 15 (41) | 33 (53) | 0.31 |
| Renal replacement therapy | 1 (3) | 11 (18) | 0.06 |
| Infectious event | 8 (22) | 28 (44) | 0.04 |
| Bacterial event | 7 (19) | 28 (44) | 0.02 |
| Pneumoniaa | 6 (16) | 23 (37) | 0.05 |
| VAP | 6 (16) | 21 (33) | 0.10 |
| Fungal event | 1 (3) | 4 (6) | 0.74 |
| ICU stay (days) | 5 [2–9] | 7 [4–17] | 0.03 |
| ICU mortality | 7 (19) | 21 (33) | 0.19 |
Data are reported as absolute value with percentage for categorical variables or median with interquartile interval for quantitative variables. ICU: Intensive Care Unit; NSAIDs: non-steroid anti-inflammatory; SAPSII: Simplified Acute Physiology Score II; SOT: Solid Organ Transplantation; VAP: Ventilator-Associated Pneumonia.
a
Pneumonia includes all lung infections occurring in non-ventilated patients and in patients with mechanical ventilation within 48 hours and after 48 hours of ventilation (VAP).